Nisen Perry 4

What Happened
Nisen Perry, a director of Teva Pharmaceutical Industries Ltd (TEVA), had 14,492 restricted share units (RSUs) vest and convert into 14,492 ordinary shares on June 5, 2026. The Form 4 reports an acquisition (conversion) of 14,492 shares and a simultaneous disposition of 14,492 shares at $0.00 (transaction code M — exercise/conversion of a derivative). No cash changed hands in the reported disposition.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 8, 2026 (timely filing).
• Reported entries: Acquired 14,492 shares (conversion of derivative); Disposed 14,492 shares at $0.00 (derivative).
• Price/Value: Acquisition reported as N/A; disposal reported at $0.00 (no proceeds).
• Footnotes:
  • F1: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share).
  • F2: Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
  • F3: These RSUs were granted on June 5, 2025 and vested on June 5, 2026.
• Shares owned after the transaction: Not specified in this Form 4.

Context
This filing reflects an RSU vesting and settlement rather than an open-market buy or sale. The simultaneous acquisition and disposition at $0.00 typically indicates shares were converted on vesting and then withheld or settled (commonly for tax-withholding or cash settlement), not a market sale for proceeds. Such derivative-settlement events are routine for equity compensation and do not by themselves indicate a bullish or bearish view by the insider.